

High-speed analysis of large sample sets – how can this key aspect of the omics be achieved?

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Access

Cramer, R. ORCID: <https://orcid.org/0000-0002-8037-2511>
(2020) High-speed analysis of large sample sets – how can
this key aspect of the omics be achieved? *Molecular and
Cellular Proteomics*, 19 (11). pp. 1760-1766. ISSN 1535-9484
doi: <https://doi.org/10.1074/mcp.P120.001997> Available at
<https://centaur.reading.ac.uk/92645/>

It is advisable to refer to the publisher's version if you intend to cite from the
work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1074/mcp.P120.001997>

Publisher: American Society for Biochemistry and Molecular Biology

All outputs in CentAUR are protected by Intellectual Property Rights law,
including copyright law. Copyright and IPR is retained by the creators or other
copyright holders. Terms and conditions for use of this material are defined in
the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

High-speed Analysis of Large Sample Sets – How Can This Key Aspect of the Omics Be Achieved?

Author

Rainer Cramer

Correspondence

r.k.cramer@reading.ac.uk

In Brief


New advances in laser-based MS with respect to analytical depth, signal robustness and sample flexibility in combination with its intrinsically high sample analysis speed can fill many of the gaps in the field of proteomics that can currently only be served with severe limitations by the commonly employed but much slower ESI-based proteomic tools, thus arguably allowing for the analysis of $\geq 1\text{M}$ samples/day on a single platform for analyses that do not require deep proteome coverage.

Highlights

- Future proteomic analyses for longitudinal studies and P4 medicine arguably require $\geq 1\text{M}$ samples/day.
- Proteome depth/coverage is commonly the focus whereas analytical speed is typically neglected.
- A compromise between analytical depth and speed is needed for future large-scale studies.
- Ultrahigh-speed 'omic' analyses require tools that are intrinsically fast such as laser-based MS.

Graphical Abstract

From Deep Coverage to Large Scale Sample Analysis



Cramer, 2020, *Mol Cell Proteomics* 19(11), 1760–1766

November 2020 © 2020 Cramer. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.

<https://doi.org/10.1074/mcp.P120.001997>



High-speed Analysis of Large Sample Sets – How Can This Key Aspect of the Omics Be Achieved?

Rainer Cramer*

High-speed analysis of large (prote)omics sample sets at the rate of thousands or millions of samples per day on a single platform has been a challenge since the beginning of proteomics. For many years, ESI-based MS methods have dominated proteomics because of their high sensitivity and great depth in analyzing complex proteomes. However, despite improvements in speed, ESI-based MS methods are fundamentally limited by their sample introduction, which excludes off-line sample preparation/fractionation because of the time required to switch between individual samples/sample fractions, and therefore being dependent on the speed of on-line sample preparation methods such as liquid chromatography. Laser-based ionization methods have the advantage of moving from one sample to the next without these limitations, being mainly restricted by the speed of modern sample stages, i.e. 10 ms or less between samples. This speed matches the data acquisition speed of modern high-performing mass spectrometers whereas the pulse repetition rate of the lasers (>1 kHz) provides a sufficient number of desorption/ionization events for successful ion signal detection from each sample at the above speed of the sample stages. Other advantages of laser-based ionization methods include the generally higher tolerance to sample additives and contamination compared with ESI MS, and the contact-less and pulsed nature of the laser used for desorption, reducing the risk of cross-contamination. Furthermore, new developments in MALDI have expanded its analytical capabilities, now being able to fully exploit high-performing hybrid mass analyzers and their strengths in sensitivity and MS/MS analysis by generating an ESI-like stable yield of multiply charged analyte ions. Thus, these new developments and the intrinsically high speed of laser-based methods now provide a good basis for tackling extreme sample analysis speed in the omics.

The “omics”, in particular proteomics, have tremendously benefited from the arrival of modern MS with its unrivaled performance in sensitivity while providing high specificity and superior multiplexing because of its exquisitely high resolu-

tion in mass separation. Simultaneous and accurate detection of numerous forms of biomolecules is easily achievable in one MS experiment. This biomolecular detection sensitivity has been exploited and further improved over the years, also in combination with up-stream sample fractionation methods, lowering the limits of detection and expanding the number of identified and quantified proteins as well as other biomolecules (metabolites, lipids, etc.). It has led to a race for higher proteome coverages with records being frequently broken as exemplified by work in the areas of phosphoproteomics (1–5) and blood plasma proteomics (6–8).

The invention and commercial manufacturing of ever newer and faster mass spectrometers were crucial for these advances into the depth of many proteomes. Orbitrap technology (9, 10) and ion mobility spectrometry (11, 12) are good examples of novel concepts of ion manipulation that supported this development. In combination with faster MS/MS and ion detection as well as faster signal readouts and new MS/MS strategies such as data-independent acquisition (DIA) (11, 13) higher proteome coverages have been obtained at increasing speed. In addition, further improvements in protein labeling methods (e.g. greater multiplexing (14)) and separation techniques (e.g. UHPLC (15, 16)) have helped to speed up the analysis of complex samples (17). Thus, new MS hardware and methods as well as advances in up-stream separation/fractionation techniques have arguably resulted in fast large-scale proteomics.

However, the impact of these advances are greatest for in-depth proteomics and the analysis of extensively processed samples that often undergo complex sample preparation protocols (1, 6, 11). These protocols typically rely on (nano) HPLC separation and frequently on further up-stream sample purification/extraction such as filter-aided sample preparation and can take a minimum of 3 days from proteolytic digestion to data evaluation (11). For the analysis of sub-proteomes, these protocols can be even more complex, including protein depletion if there is a large protein abundance range such as in blood (6), or specific peptide/protein enrichment by affinity purification as it is the case in phosphoproteomics (1). For

From the Department of Chemistry, University of Reading, Whiteknights, Reading, RG6 6DX, UK

* For correspondence: Rainer Cramer, r.k.cramer@reading.ac.uk.




FIG. 1. Comparison of reported sample analysis speeds for various peer-reviewed high-speed MS approaches. Please note that the size of each circle does not accurately reflect the exact analysis speed for each MS approach. AP: atmospheric pressure; VS MALDI: vacuum solid MALDI; DESI: desorption electrospray ionization; LDTD: laser diode thermal desorption.

obvious reason, such thoroughly prepared samples are somewhat limited in numbers, simply by the fact that these are prepared in specialized laboratory, of which there are only a few in existence.

Some of the latest advances in deep proteome analysis now allow the confident identification of >10 (HeLa cell line) proteomes per day at a depth of nearly 8000 identified proteins using TMT labeling/multiplexing (4) whereas new data mining software based on neural networks can substantially improve the number of confident precursor peptide identifications within a DIA bottom-up proteomics analysis approach (18). Both strategies easily lead to an in-depth analysis (>5000 proteins; >50,000 peptide precursors) of 10–20 (HeLa) proteomes per day on a single MS instrument. Further improvements in this area can be expected and one day might allow the analysis of 100 or more proteomes per day, though in the near future most likely only at the expense of proteome coverage.

However, there seems to be no major movement toward extremely fast omic analysis of several samples per seconds for extremely large sample sets, *i.e.* millions or even billions of samples, despite the realization that baseline abundances of specific proteoforms or other biomolecular species can substantially vary among (healthy) individuals, in particular in the human population (19–21), and thus for diagnostic purposes ultimately demanding frequent longitudinal sampling of all individuals in a given population. Only this type of large-scale sampling and subsequent (prote)omic analysis will provide the much-needed data for advancing the understanding of population-wide proteome changes and exploiting protein/proteome analysis for improved diagnostics and therapeutics. For population-wide preventive medicine, frequent measurements of an individual's proteome (or subsets of it) will be the next crucial step in clinical proteomics with the potential to fulfill the promises of the much-heralded future of personalized and precision medicine.

Unfortunately, the scale and speed for this type of proteomics is far from achievable with the analytical tools currently employed, especially with those for in-depth proteome analysis. Thus, it seems reasonable to consider a departure from exclusively focusing on these tools and the quest for comprehensiveness.

Regarding MS-based methods, the coupling of slow separation/fractionation methods such as chromatography to ESI has served the first decades of proteomics well. Many proteomes have been qualitatively and (to a lesser) extent quantitatively catalogued and compared in depth, though typically only from a few biological replicates and time points as the price for in-depth analysis are analysis times of hours, at the best tens of minutes per sample (18). Even multiplexing using current labeling methodologies cannot provide the means for the analysis of millions, let alone billions of samples per day.

Consequently, the low speed of up-stream sample fractionation and ESI need to be addressed. With respect to ESI, a handful of groups have considered improvements of its sample introduction and thus sample-to-sample speed. These efforts have led to sample analysis rates of seconds per sample (22, 23), in some cases even up to 6 samples per second, though with the caveat of a relatively convoluted (micro)fluidic sample introduction system (24). However, the latter proof-of-principle study was shown with the small drug molecule dextromethorphan and its primary metabolite dextrophan rather than with peptides or proteins as analytes. Although up to 6 samples per second is extremely fast compared with conventional ESI MS analysis, it could well be its limit, given the practical difficulties of rapidly changing samples and achieving a stable electrospray in this time frame.

Fortunately, there are other (soft) ionization methods in MS that are well suited for fast sample turn-over rates. These methods typically benefit from the off-line preparation of samples on a stage that can be moved from sample to sample at extreme speed. Ionization of these samples can be achieved by either scanning over the samples using

continuous ionization methods (e.g. DESI(25)) or equally fast pulsed ionization methods (e.g. SAWN (26), AMI (27)). Fig. 1 provides a comparison of sample analysis speeds for various reported high-speed MS approaches.

The ultimate tools for fast ionization are lasers with their well-defined beams and stable energy output, providing nanosecond or shorter pulses of high energy focused onto a small desorption area. Lasers can provide soft ionization events at high repetition rates (>1 kHz) with sufficient ion yield from a single laser shot. Thus, in laser-based MS the time to analyze a sample is ultimately limited by the speed of the sample stage and the mass analyzer. Currently, these devices allow analysis times of 10–50 ms or less per sample, *i.e.* 20–100 data acquisitions (samples) per second or up to 8.6 million samples per day. This rough calculation assumes continuous sample supply as might be possible using a conveyor belt set-up. However, the up-stream and on-line nature of using conveyor belt technology would realistically require several sample preparation stations along the conveyor belt with all the disadvantages of a complex on-line multi-station up-stream sample preparation system. A more practical scenario is the use of microtiter plates as a standard format, which provides a truly off-line and scalable sample preparation system that can be set up with the required number of commercial sample preparation stations needed for feeding the mass spectrometer at the applicable sample throughput. In this case, additional time for changing plates needs to be added. Using modern robotics, microtiter plates can be easily changed within 5 s, and with formats of high sample density such as 1536-well microtiter plates, rates of ~6.5 million samples analyzed per day should be feasible on one laser-based MS instrument. Roughly 1000–2000 of these analytical platforms would therefore be sufficient for analyzing 1 sample per human being per day.

Data transfer, processing and further mining at these high data acquisition speeds might then arguably present the next challenge, which will also depend on the exact use of meta-data and database searching. Even more challenging will be the logistics behind individual sample collection and delivery to the laboratory at this scale. Interestingly, these questions have recently become highly topical as part of the COVID-19 testing response and calls for developing future delivery systems such as small drone deliveries (*cf.* UK Research and Innovation's Future Flight Challenge).

A maximum sample analysis rate of 100 samples per second is typically based on the acquisition of MS profiles without any subsequent MS/MS data collection. Depending on the exact requirements, such as the desired depth of analysis, this rate can obviously be reduced by any factor, thus allowing MS/MS experiments to be carried out on precursor ions of interest in the acquired MS profile. For example, reducing the sample analysis rate from 100 to 10 samples per second would allow the MS/MS analysis of 9 precursor peptide/protein ions from the acquired MS profile. For com-

plex proteome samples, pre-fractionation might also be desirable and the possible 100 MS (or MS/MS) data acquisitions might be used on 20 proteome fractions each being analyzed by one precursor ion scan/profile and 4 subsequent MS/MS analyses per precursor ion profile. In this simple data-dependent acquisition (DDA) scenario, 80 precursor ions could be identified by MS/MS sequencing in 1 s or up to 80,000 in 1000s or less than 17 min. Using a DIA analysis strategy, 500 LC fractions of a digest mixture from one proteome sample could be analyzed by switching continuously between MS and MS/MS data acquisition, resulting in 1000 data acquisitions that require only 10s of analysis time. With a 2-kHz laser each data acquisition can benefit from 10–20 individual desorption events, which in the case of MALDI only consume a fraction of the peptide amount in each LC fraction but are sufficient for the analysis of low femtomole amounts of peptides. These examples clearly demonstrate that in-depth proteome analysis can also benefit from the speed of laser-based ionization with the additional advantage of enabling much greater sample analysis speed if less depth can be tolerated.

Platforms using pulsed lasers are also ideal set-ups for avoiding cross-contamination or carry-overs from previous samples as lasers provide the necessary desorption energy in a contact-less way with the desorption/ionization events being discrete and shorter in time (nanoseconds) than the time it takes to move from one sample to the next. Thus, laser-based ionization techniques are ideal for rapid, highly controllable desorption/ionization for MS analysis.

An important feature of all these techniques is off-line sample preparation, allowing the use of multiple sample preparation stations as feeder devices to the analytical MS system. Thus, up-stream bottlenecks reducing the ultimate sample analysis speed can be easily avoided and the speed in sample analysis will roughly increase with the number of off-line sample preparation platforms. Off-line sample preparation also provides greater flexibility regarding specific requirements in sample preparation and enables easier adaptation of new sample preparation methods and their associated instrumentation.

Nonetheless, given current performance data, moving away from ESI- to laser-based MS analyses for greater speed is likely to lead to a loss of overall sensitivity, even if the same or a similar sample pre-fractionation methods were employed and MALDI was used as the softest and most sensitive laser-based ionization technique (28, 29). For proteomics analysis, ESI-based methods are currently the most sensitive, providing the greatest proteome coverages, particularly in combination with on-line LC separation. However, compared with ESI, MALDI has competitive advantages in three important analytical areas, namely scalability, speed, and sample flexibility. Sample flexibility, *i.e.* flexibility with regard to the overall sample conditions, is important if these conditions need to be adjusted to provide an optimal

Relative MS Performance Data for Four Soft Ionization Techniques



FIG. 2. Relative comparison between ESI, DESI, MALDI, and liquid AP-MALDI with respect to their MS performance in six analytical areas (sensitivity, scalability, speed, signal stability, sample flexibility, and structural elucidation) on a scale from 0 (center; lowest performance in biomolecular detection) to 10 (outer line; best performance in biomolecular detection).

environment for the analyte to be ionized and detected, or equally important, if sample conditions are sub-optimal but would take a lot of time to ‘clean up’ for best ionization results. The latter would have a direct impact on the time needed for sample preparation. In combination with the advantages in scalability, which are partially a result of off-line sample preparation, and speed (because of the above-mentioned laser characteristics), MALDI is ideal for high-speed biomolecular analysis of extremely large sample sets. Taking its good performance in low-speed in-depth proteomic analysis (and MS imaging) into account MALDI is probably the most versatile proteomic tool.

A relative comparison of the analytical performance of ESI, DESI, (conventional solid-state) MALDI and liquid AP-MALDI in six important areas (sensitivity, scalability, speed, signal stability, sample flexibility, and structural elucidation) is shown in Fig. 2.

Employing MALDI instead of ESI and exploiting its capabilities in high-speed MS profiling of large sample sets, undoubtedly results in a reduction of the number of biomolecules that will be detected. Nevertheless, recent developments have shown that fast MALDI MS profiling has gained further depth. The use of heated atmospheric pressure (AP) ion sources on hybrid mass analyzers and liquid MALDI sample preparation methods that facilitate the production of multiply charged proteinaceous analyte ions have significantly contributed to these developments (30). The combination of these recent advances that add additional functionalities to

(prote)omic profiling by MALDI MS, which in its earlier form was significantly less-advanced and ultimately unsuccessful in accurate disease diagnostics (*cf.* SELDI (31)), could soon become sufficiently sensitive for the detection of important peptide/protein panels and other molecular biomarkers that can be further exploited for clinical diagnostics as well as for understanding the underlying (systems) biology (30). Some of the earlier shortcomings of MALDI MS(/MS) profiling such as poor biomarker identification/verification from the same sample can now be addressed at greater speed, enabling rapid analysis of large sample sets together with a meaningful level of depth in (prote)omic biomarker detection. These newly gained advances in (bio)molecular detection at high speed also provides additional power and flexibility in devising large-scale nonclinical (prote)omic analyses, including compound library screening in biopharmaceutical research and environmental screening at extreme speed (32–34).

Furthermore, liquid AP-MALDI MS as one of the newly introduced MALDI MS approaches has the potential to offer kinetics measurements, *e.g.* of enzymatic reactions, on target and in real time within the mass spectrometer because of the liquid state of the MALDI sample (35). In general, liquid MALDI samples provide greater flexibility for creating specific sample conditions (*e.g.* through a greater choice of additives) that are desirable for certain types of analytes/analyses but are not achievable with solid MALDI samples or are incompatible with other liquid-based ionization techniques such as ESI (36, 37). One prominent example is the use of

trifluoroacetic acid (TFA), which has been abandoned in LC-ESI MS/MS proteomic analysis because of its incompatibility with ESI. Ryumin *et al.* have shown in an LC-MALDI MS/MS study of protein digests that liquid MALDI can tolerate the use of TFA, providing the same protein sequence coverage and performance as formic acid (37). In the same study, other useful advantages of liquid MALDI were demonstrated such as the low consumption of the prepared MALDI sample, potentially allowing the recovery of most of the digest (arguably up to 99%). Furthermore, medium- to long-term MALDI sample archiving in -20°C freezers was possible without suffering any loss of analytical performance and information when the samples were re-analyzed after these storage conditions. The two main advances provided by liquid MALDI, however, are the extremely robust and stable ion yield as demonstrated by Palmblad *et al.* (38) and the recently discovered possibility of generating ESI-like multiply charged ions under atmospheric pressure (39). It was shown that with the robust and stable ion yield much higher reproducibility is achievable, resulting in low ion signal fluctuations similar to nanoESI and standard deviations for database search results of protein digest replicate analyses at around 5-10% or less compared with 10-25% or more for solid MALDI, particularly for low-purity samples (40). The second main advance, the production of ESI-like multiply charged ions, allows the use of high-performing hybrid mass analyzers with a typically small m/z range as found in Q-TOF and hybrid orbitrap instruments. It therefore results in post-source MS/MS peptide sequencing in the same way as for ESI-generated peptide ions, without any indication of a difference in fragmentation related to the origin of these ions (37, 39) – for in-source fragmentation, however, fragment ion generation appears to be dependent on the exact matrix being used and therefore different to ESI (41). This new and unique feature in MALDI MS was exploited by Hale *et al.* for identifying discriminative protein fragments in liquid AP-MALDI MS profiling for the accurate detection of bovine mastitis from extremely small amounts of milk (30). Interestingly, liquid AP-MALDI MS profiling on a Q-TOF instrument also revealed another advantage of this MALDI/Q-TOF combination as it showed that small molecules such as metabolites and lipids can be effectively co-detected together with larger peptides and proteins in a single spectrum (30, 42). In conventional (vacuum) MALDI MS using axial TOF instruments usually only one or the other can be effectively analyzed because of the difference in acquisition modes employed for small molecules (high-resolution reflectron mode) and larger molecules such as proteins (linear mode with increased laser energy, and thus extremely high amounts of ions in the lower m/z range, which are normally suppressed before and/or at the detection step). Thus, liquid AP-MALDI MS provides a greater range of accessible analytes that can be detected in the same spectrum, making comprehensive biomolecular profiling by MALDI MS potentially more powerful than that offered by current methods using conventional (solid-

state and vacuum) MALDI MS profiling as available in commercial MALDI MS biotyping platforms.

The potential of these new developments in MALDI in addition to the well-known fundamental advantages of a laser-based analytical method (*e.g.* in speed) have so far attained little attention. With these new step changes being made in MALDI MS-based methods it now seems to be a good time to (re)consider extreme high-speed and large-scale proteomics with all its potential in gaining additional information for biological systems analysis and disease diagnostics.

In this context it has to be noted that the recent large influx of new acronyms for supposedly novel (laser) ionization techniques, without scrutinizing the technique's analytical usefulness and in many cases its novelty, let alone the need for creating a new acronym, has not been helpful. In fact, it confuses the field and makes it difficult to find true advances. As a result, many groups are deterred from further exploring truly novel and advantageous developments in this area.

Finally, nonMS proteomic tools such as immunoassays and enzymatic activity assays seem to be in many cases good alternatives for large-scale and high-speed proteomics (43, 44). In virtually all cases, however, the highly targeted nature of these assays and the time often needed for the necessary reactions and readouts disqualify these methods as serious competitors. In many cases, issues with respect to specificity, traceability and development costs are further aspects that render them ultimately uncompetitive. Nevertheless, it must be noted that the one strong advantage of such methods is the possibility of point-of-care and in-field applications, which is still a weak point for all current MS-based (prote)omic analyses.

In conclusion, after the advent of modern MS in the omics and its stellar rise as the analytical method of choice, MS has further advanced in areas of its obvious strength such as high sensitivity and specificity in biomolecular detection, mainly as a result of further improvements in mass analyzers (including greater mass measurement resolution and accuracy), sample preparation methods and separation/fractionation techniques. ESI-based methods have been for most of these advances the obvious choice and at the center for further improvements. As a direct result some areas such as high-speed and large-scale (prote)omic analysis of large numbers of biological samples have been challenging and therefore somewhat neglected. There have been advances in these areas however and it is now feasible to undertake (prote)omic analysis of millions of samples at much higher speed using nonESI-based methods. These analyses might never provide the depth of LC-ESI MS/MS with all its improvements made over decades (*e.g.* nanoESI, UHPLC, multiplex labeling, ...) but will be able to provide some depth in biomolecular detection, partially benefitting from the same MS hardware that also improved ESI-based analyses. Importantly, these nonESI-based methods can

offer the speed and scalability that is still missing to satisfy the requirements for population-wide and longitudinal sample collections. Achieving the latter will not only help the advancement of personalized and precision medicine but also provide invaluable data regarding population-wide and environment-/time-specific changes of the proteome. Although critical voices might argue that the biomolecular coverage will never be as great as with LC-ESI-based MS analyses, it would seem to be grossly negligent to ignore the additional richness of the omic and system information that large sample sets collected over various dimensions can offer. Even if it will never be possible to analyze the entire proteome by these methods – as will probably never be possible with an ESI-based MS method either – there are now clear indications that the analytical depth is sufficient to pursue (prote)omic analyses at the speed of thousands or more samples per day (34, 37). The analysis of a million samples per day on a single MS platform is also well within the capabilities of laser-based ionization techniques, though here it remains to be seen whether more than a hundred biomolecular species can be analyzed at this speed. Early data obtained by the laser-based method of liquid AP-MALDI using high-performing hybrid mass analyzers are encouraging and indicate that analysis at this speed and depth are entirely possible in the foreseeable future (34). Importantly, the analytical depth, signal robustness and sample flexibility of this new approach is well beyond early MS profiling methods using conventional, solid-state MALDI on axial TOF mass analyzers. These extremely fast analyses would then be able to fill many of the gaps in the field of proteomics that can currently only be served with severe limitations by the commonly employed but much slower ESI-based proteomic tools.

Funding and additional information—This work was supported in part by the BBSRC (grant BB/R002975/1).

Author contributions—R.C. wrote the paper.

Conflict of interest—Authors declare no competing interests.

Abbreviations—The abbreviations used are: DIA, data-independent acquisition; ESI, electrospray ionization; DDA, data-dependent acquisition.

Received February 21, 2020, and in revised form, July 29, 2020
Published, MCP Papers in Press, August 12, 2020, DOI 10.1074/mcp.P120.001997

REFERENCES

- Humphrey, S. J., Karayel, O., James, D. E., and Mann, M. (2018) High-throughput and high-sensitivity phosphoproteomics with the EasyPhos platform. *Nat. Protoc.* **13**, 1897–1916
- Possemato, A. P., Paulo, J. A., Mulhern, D., Guo, A., Gygi, S. P., and Beausoleil, S. A. (2017) Multiplexed phosphoproteomic profiling using titanium dioxide and immunoaffinity enrichments reveals complementary phosphorylation events. *J. Proteome Res.* **16**, 1506–1514
- Sharma, K., D'Souza, R. C. J., Tyanova, S., Schaab, C., Wiśniewski, J. R., Cox, J., and Mann, M. (2014) Ultra-deep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. *Cell Rep.* **8**, 1583–1594
- Bian, Y., Zheng, R., Bayer, F. P., Wong, C., Chang, Y. C., Meng, C., Zolg, D. P., Reinecke, M., Zecha, J., Wiechmann, S., Heinzlmeier, S., Scherr, J., Hemmer, B., Baynham, M., Gingras, A. C., Boychenko, O., and Kuster, B. (2020) Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC-MS/MS. *Nat. Commun.* **11**, 157
- Riley, N. M., and Coon, J. J. (2016) Phosphoproteomics in the age of rapid and deep proteome profiling. *Anal. Chem.* **88**, 74–94
- Keshishian, H., Burgess, M. W., Specht, H., Wallace, L., Clauser, K. R., Gillette, M. A., and Carr, S. A. (2017) Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry. *Nat. Protoc.* **12**, 1683–1701
- Cao, Z. J., Tang, H. Y., Wang, H., Liu, Q., and Speicher, D. W. (2012) Systematic comparison of fractionation methods for in-depth analysis of plasma proteomes. *J. Proteome Res.* **11**, 3090–3100
- Farrah, T., Deutsch, E. W., Omenn, G. S., Campbell, D. S., Sun, Z., Bletz, J. A., Mallick, P., Katz, J. E., Malmstrom, J., Ossola, R., Watts, J. D., Lin, B. A. Y., Zhang, H., Moritz, R. L., and Aebersold, R. (2011) A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. *Mol. Cell. Proteomics* **10**, M110.006353
- Michalski, A., Damoc, E., Hauschild, J. P., Lange, O., Wieghaus, A., Makarov, A., Nagaraj, N., Cox, J., Mann, M., and Horning, S. (2011) Mass spectrometry-based proteomics using Q Exactive, a high-performance benchtop quadrupole orbitrap mass spectrometer. *Mol. Cell. Proteomics* **10**, M111.011015
- Geiger, T., Cox, J., and Mann, M. (2010) Proteomics on an orbitrap benchtop mass spectrometer using all-ion fragmentation. *Mol. Cell. Proteomics* **9**, 2252–2261
- Distler, U., Kuharev, J., Navarro, P., and Tenzer, S. (2016) Label-free quantification in ion mobility-enhanced data-independent acquisition proteomics. *Nat. Protoc.* **11**, 795–812
- Daly, C. E., Ng, L. L., Hakimi, A., Willingale, R., and Jones, D. J. (2014) Qualitative and quantitative characterization of plasma proteins when incorporating traveling wave ion mobility into a liquid chromatography-mass spectrometry workflow for biomarker discovery: use of product ion quantitation as an alternative data analysis tool for label free quantitation. *Anal. Chem.* **86**, 1972–1979
- Chapman, J. D., Goodlett, D. R., and Masselon, C. D. (2014) Multiplexed and data-independent tandem mass spectrometry for global proteome profiling. *Mass Spectrom. Rev.* **33**, 452–470
- Myers, S. A., Rhoads, A., Cocco, A. R., Peckner, R., Haber, A. L., Schweitzer, L. D., Krug, K., Mani, D. R., Clauser, K. R., Rozenblatt-Rosen, O., Hacohen, N., Regev, A., and Carr, S. A. (2019) Streamlined protocol for deep proteomic profiling of FAC-sorted cells and its application to freshly isolated murine immune cells. *Mol. Cell. Proteomics* **18**, 995–1009
- Scollo, E., Neville, D., Oruna-Concha, M. J., Trotin, M., and Cramer, R. (2018) Characterization of the proteome of theobroma cacao beans by Nano-UHPLC-ESI MS/MS. *Proteomics* **18**, 1700339
- Kocher, T., Swart, R., and Mechtler, K. (2011) Ultra-high-pressure RPLC hyphenated to an LTQ-orbitrap velos reveals a linear relation between peak capacity and number of identified peptides. *Anal. Chem.* **83**, 2699–2704
- Cominetti, O., Galindo, A. N., Corthesy, J., Moreno, S. O., Irincheeva, I., Valdesia, A., Astrup, A., Saris, W. H. M., Hager, J., Kussmann, M., and Dayon, L. (2016) Proteomic biomarker discovery in 1000 human plasma samples with mass spectrometry. *J. Proteome Res.* **15**, 389–399
- Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S., and Ralser, M. (2020) DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. *Nat. Methods* **17**, 41–44
- Aebersold, R., Agar, J. N., Amster, I. J., Baker, M. S., Bertozzi, C. R., Boja, E. S., Costello, C. E., Cravatt, B. F., Fenselau, C., Garcia, B. A., Ge, Y., Gunawardena, J., Hendrickson, R. C., Hergenrother, P. J., Huber, C. G., Ivanov, A. R., Jensen, O. N., Jewett, M. C., Kelleher, N. L., Kiessling, L. L., Krogan, N. J., Larsen, M. R., Loo, J. A., Ogorzalek Loo, R. R., Lundberg, E., MacCoss, M. J., Mallick, P., Mootha, V. K., Mrksich, M., Muir, T. W., Patrie, S. M., Pesavento, J. J., Pitteri, S. J., Rodriguez, H., Saghatelian, A., Sandoval, W., Schluter, H., Sechi, S., Slavoff, S. A., Smith, L. M., Snyder, M. P., Thomas, P. M., Uhlen, M., Van Eyk, J. E., Vidal, M., Walt, D. R., White, F. M., Williams, E. R., Wohlschlagel, T., Wysocki, V. H., Yates, N. A., Young, N. L., and Zhang, B. (2018) How many human proteoforms are there?. *Nat. Chem. Biol.* **14**, 206–214

20. Wu, L. F., Candille, S. I., Choi, Y., Xie, D., Jiang, L. H., Li-Pook-Than, J., Tang, H., and Snyder, M. (2013) Variation and genetic control of protein abundance in humans. *Nature* **499**, 79–82
21. Pakharukova, N. A., Pastushkova, L. K., Moshkovskiy, S. A., and Larina, I. M. (2012) [Variability of healthy human proteome]. *Biomed. Khim.* **58**, 514–529
22. Bretschneider, T., Ozbal, C., Holstein, M., Winter, M., Buettner, F. H., Thamm, S., Bischoff, D., and Luippold, A. H. (2019) RapidFire BLAZE-mode is boosting ESI-MS toward high-throughput-screening. *SLAS Technol.* **24**, 386–393
23. Rohman, M., and Wingfield, J. (2016) High-throughput screening using mass spectrometry within drug discovery. *High Throughput Screening: Methods and Protocols*, 3rd Edition **1439**, 47–63
24. Häbe, T. T., Runge, F., Liu, C., Covey, T. R., and Luippold, A. H. (2020) The fastest ESI-MS: Mass spectrometry analysis up to six samples per second by acoustic ejection. Proceedings of the 68th Conference on Mass Spectrometry and Allied Topics, TP 139
25. Takats, Z., Wiseman, J. M., Gologan, B., and Cooks, R. G. (2004) Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. *Science* **306**, 471–473
26. Heron, S. R., Wilson, R., Shaffer, S. A., Goodlett, D. R., and Cooper, J. M. (2010) Surface acoustic wave nebulization of peptides as a microfluidic interface for mass spectrometry. *Anal. Chem.* **82**, 3985–3989
27. Sinclair, I., Stearns, R., Pringle, S., Wingfield, J., Datwani, S., Hall, E., Ghislain, L., Majlof, L., and Bachman, M. (2016) Novel acoustic loading of a mass spectrometer: toward next-generation high-throughput MS screening. *J. Lab. Autom.* **21**, 19–26
28. Nadler, W. M., Waidelich, D., Kerner, A., Hanke, S., Berg, R., Trumpp, A., and Rosli, C. (2017) MALDI versus ESI: The impact of the ion source on peptide identification. *J. Proteome Res.* **16**, 1207–1215
29. Ruprecht, B., Roesli, C., Lemeere, S., and Kuster, B. (2016) MALDI-TOF and nESI Orbitrap MS/MS identify orthogonal parts of the phosphoproteome. *Proteomics* **16**, 1447–1456
30. Hale, O. J., Morris, M., Jones, B., Reynolds, C. K., and Cramer, R. (2019) Liquid atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry adds enhanced functionalities to MALDI MS profiling for disease diagnostics. *Acs Omega* **4**, 12759–12765
31. Diamandis, E. P. (2003) Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?. *Clin. Chem.* **49**, 1272–1275
32. Winter, M., Ries, R., Kleiner, C., Bischoff, D., Luippold, A. H., Bretschneider, T., and Buttner, F. H. (2019) Automated MALDI target preparation concept: providing ultra-high-throughput mass spectrometry-based screening for drug discovery. *SLAS Technol.* **24**, 209–221
33. Haslam, C., Hellicar, J., Dunn, A., Fuetterer, A., Hardy, N., Marshall, P., Paape, R., Pemberton, M., Resemannand, A., and Leveridge, M. (2016) The evolution of MALDI-TOF mass spectrometry toward ultra-high-throughput screening: 1536-well format and beyond. *J. Biomol. Screen.* **21**, 176–186
34. Krenkel, H., Hartmane, E., Piras, C., Brown, J., Morris, M., and Cramer, R. (2020) Advancing liquid atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry toward ultrahigh-throughput analysis. *Anal. Chem.* **92**, 2931–2936
35. Towers, M., and Cramer, R. (2007) Liquid matrices for analyses by UV-MALDI mass spectrometry. *Spectroscopy* **22**, 29
36. Hale, O. J., Ryumin, P., Brown, J. M., Morris, M., and Cramer, R. (2018) Production and analysis of multiply charged negative ions by liquid atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry. *Rapid Commun. Mass Spectrom.* **2018**, 1–8. <http://dx.doi.org/10.1002.rcm.8246>
37. Ryumin, P., Brown, J., Morris, M., and Cramer, R. (2017) Protein identification using a nanoUHPLC-AP-MALDI MS/MS workflow with CID of multiply charged proteolytic peptides. *Int. J. Mass Spectrom.* **416**, 20–28
38. Palmblad, M., and Cramer, R. (2007) Liquid matrix deposition on conductive hydrophobic surfaces for tuning and quantitation in UV-MALDI mass spectrometry. *J. Am. Soc. Mass Spectrom.* **18**, 693–697
39. Cramer, R., Pirkel, A., Hillenkamp, F., and Dreisewerd, K. (2013) Liquid AP-UV-MALDI enables stable ion yields of multiply charged peptide and protein ions for sensitive analysis by mass spectrometry. *Angew. Chem. Int. Ed. Engl.* **52**, 2364–2367
40. Towers, M. W., McKendrick, J. E., and Cramer, R. (2010) Introduction of 4-chloro-alpha-cyanocinnamic acid liquid matrices for high sensitivity UV-MALDI MS. *J. Proteome Res.* **9**, 1931–1940
41. Ait-Belkacem, R., Dillillo, M., Pellegrini, D., Yadav, A., de Graaf, E. L., and McDonnell, L. A. (2016) In-Source Decay and Pseudo-MS(3) of Peptide and Protein Ions Using Liquid AP-MALDI. *J. Am. Soc. Mass Spectrom.* **27**, 2075–2079
42. Lellman, S. E., and Cramer, R. (2020) Bacterial identification by lipid profiling using liquid atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry. *Clin. Chem. Lab. Med.* **58**, 930–938
43. Lin, Q., Wu, J., Fang, X., and Kong, J. (2020) Washing-free centrifugal microchip fluorescence immunoassay for rapid and point-of-care detection of protein. *Anal. Chim. Acta* **1118**, 18–25
44. Yamagishi, M., Ohara, O., and Shirasaki, Y. (2020) Microfluidic immunoassays for time-resolved measurement of protein secretion from single cells. *Annu. Rev. Anal. Chem. (Palo Alto Calif)* **13**, 67–84